Novartis Coartem Malaria NDA May Be First For Priority Review Voucher
Executive Summary
Novartis' pending application for approval of the malaria treatment Coartem (artemether/lumefantrine) puts the company in line to be among the first to obtain a priority review voucher from FDA
You may also be interested in...
Priority Review Vouchers One Step Closer, But Congress Must Act Again
FDA will not be able to review applications covered by a priority review voucher until it receives Congressional authorization to collect a special user fee to support the program, the agency says in a draft guidance on the new incentive for pharmaceutical companies
Priority Review Vouchers One Step Closer, But Congress Must Act Again
FDA will not be able to review applications covered by a priority review voucher until it receives Congressional authorization to collect a special user fee to support the program, the agency says in a draft guidance on the new incentive for pharmaceutical companies
Priority Review Vouchers One Step Closer, But Congress Must Act Again
FDA guidance on incentive for neglected tropical disease research clarifies some key questions—but also stresses need for appropriation authority to make program work.